Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 623 results for "ranbaxy laboratories"

Sun Pharma, Ranbaxy extends fall on US FDA's surprise plant inspection
Business Standard

Sun-Ranbaxy deal: CCI public scrutiny deadline ends today

Fair trade watchdog CCI's deadline for public comments on the USD 4 billion Sun Pharmaceuticals-Ranbaxy Laboratories deal, which has raised concerns of adverse impact on competition, ends The Hindu, 6 days ago
Benefit of Ranbaxy deal to accrue in few years: Sun Pharma Business Standard India, 1 day ago
[x]  

161 images for ranbaxy laboratories

Sify, 1 week ago
Reuters India, 6 days ago
Yahoo! News, 1 week ago
Reuters India, 1 week ago
Financial Express, 1 week ago
Reuters, 3 weeks ago
Business Standard, 4 days ago
MSN India, 2 weeks ago
4 Traders, 1 month ago
Financial Express, 3 weeks ago
4 Traders

Ranbaxy Laboratories' Q2 results on October 28, 2014

Ranbaxy Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 28, 2014, inter alia, to consider and approve Standalone and Consolidated Unaudited Financial Results for the second quarter ...
 Moneycontrol.com1 day ago Ranbaxy Laboratories: Outcome of court convened meeting of equity shareholders  Money Control6 days ago Ranbaxy Laboratories Ltd Company Profile: New analysis released  TransWorldNews3 weeks ago Ranbaxy Laboratories receives direction from CCI  Money Control1 month ago
[x]  

Ranbaxy Laboratories to hold board meeting

On 28 October 2014
 Business Standard1 day ago Ranbaxy Laboratories receives Civil Investigative Demand  Capital Market1 week ago Ranbaxy Laboratories Ltd receives Civil Investigative Demand ("CID") from the United States Department of Justice  Equity Bulls1 week ago Ranbaxy Laboratories to hold EGM  Capital Market1 month ago
Business Standard

Sun Pharma, Ranbaxy Laboratories rally over 5%

Sun Pharma rallied 5.4% to Rs 816, while Ranbaxy Laboratories surged 6.3% to Rs 610 on NSE. SI Reporter | Mumbai September 26, 2014 Last Updated at 11:03 IST Shares of Sun Pharmaceutical Industries and Ranbaxy Laboratories have rallied over 5% each in ...
 Business Standard4 days ago Ranbaxy Laboratories (₹574.3)  Hindu Business Line1 week ago Sun Pharma hopes to turn around Ranbaxy in four years of closing deal  Domain-B2 weeks ago Shares of pharma cos fall of FDA inspection report in Sun Pharma  India Infoline2 weeks ago
[x]  
Domain-B

Ranbaxy Laboratories stock up 4%

The stock has hit a high of Rs627 and a low of Rs607.
 India Infoline1 day ago Ranbaxy stock surges 6%  India Infoline4 days ago Ranbaxy stock up on winning dismissal of antitrust lawsuit over Lipitor  India Infoline2 weeks ago Pfizer, Ranbaxy win...  The Echo Of India2 weeks ago
[x]  
Rediff.com

Podcast (Tamil): Ranbaxy Laboratories

 Hindu Business Line1 week ago Podcast: Ranbaxy Laboratories (English) by Divya Pushkarna  Hindu Business Line1 week ago Ranbaxy Laboratories : US DEMANDS PRICING DATA FROM RANBAXY  4 Traders1 week ago Ranbaxy Laboratories : EPIRUS Biopharmaceuticals' Remicade Biosimilar Gets Final Approvals in India  4 Traders1 week ago
Rediff.com

Ranbaxy under US lens

Ranbaxy Laboratories today said the US justice department had asked it to disclose the way it priced some drugs it sold in America. The Indian company, in fact, had made a provision of Rs 237.75 crore in the first quarter but had not gone into the details. It ...
 The Telegraph1 week ago US Justice Dept demands drug pricing info from Ranbaxy  Rediff.com1 week ago US Justice Dept Asks Ranbaxy for Drug Pricing Information  Outlook1 week ago
Sify

Price cuts to hit ranbaxy, cipla most

Ranbaxy Laboratories Ltd (RLL) and Cipla are among the companies that could be impacted the most by the new price cuts announced by the National Pharma Pricing Authority (NPPA). The NPPA has capped prices of 43 formulations, ...
 4 Traders1 week ago Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others  Yahoo! Finance2 weeks ago US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others  NDTV Profit2 weeks ago Hepatitis C Drug to be Offered Soon in India at Only One Percent of Its Cost in USA  Med India2 weeks ago
[x]  
First Post.com

Ranbaxy says U.S. authorities seek information on pricing data

MUMBAI (Reuters) - Generic drugmaker Ranbaxy Laboratories Ltd ( RANB.NS ) said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid ...
 First Post.com1 week ago Ranbaxy Laboratories Ltd says US authorities seek information on pricing data  Economic Times1 week ago India's Ranbaxy says U.S. authorities seek information on pricing data  Reuters1 week ago Ranbaxy Laboratories posts loss in June quarter  Business Standard2 months ago

Shasun Pharma to merge with Strides in all-stock deal [Mint, New Delhi :: ]

Sept. 29--MUMBAI -- Six months after the announcement of a merger of drug maker Ranbaxy Laboratories Ltd For the merger, Shasun shareholders will receive five equity shares of Strides for every 16 shares held by them. The combination of ...
 BusinessWeek1 day ago Strides, Shasun pop merger pill  Calcutta Telegraph23 hours ago Strides, Shasun announce merger; to create Rs 2,500 cr entity  Business Standard India1 day ago Strides, Shasun Announce Merger, To Create Rs 2,500-cr Entity  Businessworld India1 day ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - ranbaxy laboratories
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less